Biotech Values

[biophud]

Dew--I am considering an investment in ZGEN. A couple of comments/questions.

1. Do you think that regulatory/comercial success of their thrombin product is factored into ZGEN's current price? IMO, I am less worried about regulatory problems, and would be more concerned with slow uptake in the marketplace.

2. How should ZGEN's relationship with Novo be factored in, if at all?

3. How much value does the rest of the pipeline have?

4. I am intrigued by their cytokine therapy for HCV; however it is still early and the treatment landscape may change.

5. I like their BLYS-antagonist program, but I am not sure how it will dintinguish itself from other molecules in development (HGSI, DNA/BIIB, and AMGN). One potential advantage is that ZGEN's TACI-Fc neutralizes both BLYS and APRIL (this could be good or bad).

biophud